- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
| Quantity: | |
|---|---|
Retatrutide (LY-3437943) is an experimental drug for obesity. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial. Retatrutide is currently in phase 3 clinical trials, one of many GLP-1 receptor agonists in development.
Retatrutide (LY-3437943) is an experimental drug for obesity. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial. Retatrutide is currently in phase 3 clinical trials, one of many GLP-1 receptor agonists in development.
